Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance”

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ OMX
Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the
development of orphan oncology drugs, was awarded the Silver Governance in the
Corporate Governance Prize (for midcap companies) category at the Eleventh
Annual Awards, held by the French economic and financial magazine AGEFI on
September 24, 2014.

Corporate Governance Prizes reward listed companies with the best corporate
governance practices - in particular as regards to the composition of the
companies’ board of directors, transparency of communication, functioning of
corporate bodies, social responsibility, and risk management. The awards are
based on the results of a survey of finance industry professionals. The
methodology is validated by a steering committee which identifies the companies’
good practices based on data provided in the annual report and reference
document.

For several years now, Onxeo has optimized its governance practices: the company
refers to the corporate governance code established by MiddleNext*. Its Board of
Directors is mostly composed of independent members, who are very committed
alongside the Management, and is governed by internal regulation; a code of
conduct has been implemented. The Company strives to communicate regularly and
precisely on its programs, achievements and accounts.

These elements, rewarded by the financial community through this “Silver
Governance” and decisive in strengthening confidence from shareholders and share
markets, come in addition to high-standard quality applied to all company’s
activities, in particular in R&D.

“We are very proud and happy to be awarded with this prize which confirms the
excellence of our governance, with efficient committees, processes, and
regulations, all key components to carry out our mission and achieve our goals
to create value. This prize, which places Onxeo alongside world-class companies
such as Boiron and Guerbet, reflects our ambition in the area of orphan oncology
drugs”, comments Patrick Langlois, Chairman of the Board of Directors of Onxeo.

*MiddleNext is an independent French association representing listed SMEs and
midcaps

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis
Beleodaq® (belinostat): Registered and available in the USA for peripheral T
-cell lymphoma
For more information, visit the website
www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fw
w 
w.onxeo.com&esheet=50950246&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=7bb6c9d1bf8a09a6c1017e34dbbe245c)

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference
Document filed with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=50950246&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=2&md5=17d6b2cf91177b360e7e0ceb4ff0d7f7)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=50950246&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=3&md5=6b09097e0c10e5f68f618765e7963b26)).
Contacts

Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
+33 1 45 58 76 00
or
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Alize RP
Caroline Carmagnol / Sophie Colin
caroline@alizerp.com / scolin@alizerp.com
+33 6 64 18 99 59 / +33 6 31 13 76 20